

<!--StartFragment-->RESULT 4

ABP69553

ID ABP69553 standard; protein; 836 AA.

XX

AC ABP69553;

XX

DT 15-JUN-2007 (revised)

DT 20-JAN-2003 (first entry)

XX

DE Human polypeptide SEQ ID NO 1600.

XX

KW Human; genome mapping; gene therapy; food supplement; virus; fungus;

KW cell-proliferative disorder; neurodegenerative disease; bacterial;

KW Parkinson's disease; Alzheimer's disease; autoimmune disease;

KW multiple sclerosis; diabetes; genetic disorder; wound; burn; infection;

KW arthritis; cytostatic; immunomodulator; nootropic; neuroprotective;

KW antiparkinsonian; antidiabetic; immunosuppressive; dermatological;

KW haemostatic; vulnerary; fungicide; antibacterial; virucide; protozoacide;

KW antiarthritic; BOND\_PC; CUB domain containing protein 1, isoform CRA\_a;

KW CUB domain containing protein 1, isoform CRA\_a [Homo sapiens];

KW CUB domain containing protein 1;

KW CUB domain containing protein 1 [Homo sapiens]; GO5194; GO6942; GO7517;

KW GO8307; GO16020; GO16021.

XX

OS Homo sapiens.

XX

PN WO200270539-A2.

XX

PD 12-SEP-2002.

XX

PF 05-MAR-2002; 2002WO-US005095.

XX

PR 05-MAR-2001; 2001US-00799451.

XX

PA (HYSE-) HYSEQ INC.

XX

PI Tang YT, Zhou P, Goodrich RW, Asundi V, Zhang J, Zhao QA, Ren F;

PI Xue AJ, Yang Y, Ma Y, Yamazaki V, Chen R, Wang Z, Ghosh M;

PI Wehrman T, Wang J, Wang D, Drmanac RT;

XX

DR WPI; 2002-759812/82.

DR N-PSDB; ABZ11770.

DR PC:NCBI; gi14328879.

DR PC:SWISSPROT; Q9H5V8.

XX

PT New polynucleotides comprising sequences assembled from expressed

PT sequence tags (ESTs), useful for treating cell-proliferative,

PT neurodegenerative, autoimmune, genetic, myeloid or lymphoid, or platelet

PT or coagulation disorders.

XX

PS Claim 9; SEQ ID NO 1600; 1012pp + Sequence Listing; English.

XX

CC The invention relates to an isolated polynucleotide (I) comprising a

CC nucleotide sequence selected from any of 948 sequences (ABZ11119-

CC ABZ12066) or their mature protein coding portion, active domain coding

CC protein or complementary sequences. The polynucleotides are useful for

CC identifying expressed genes or for physical mapping of human genome. The

CC encoded polypeptides (ABP68902-ABP69849) are useful as molecular weight

CC markers, as a food supplement, for generating antibodies, in medical

CC imaging, screening and diagnostic assays and for treating cell-

CC proliferative disorders (cancer), neurodegenerative diseases (Parkinson's

CC or Alzheimer's disease), autoimmune diseases (multiple sclerosis,  
 CC diabetes, lupus) genetic disorders, myeloid or lymphoid disorders,  
 CC platelet or coagulation disorders, wound, burns, incision, ulcers, liver  
 CC or lung fibrosis, infections (bacterial, viral, fungal, parasitic),  
 CC arthritis, etc. Note: The sequence data for this patent did not form part  
 CC of the printed specification, but was obtained in electronic format  
 CC directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
 CC  
 CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed  
 CC information from BOND.  
 XX  
 SQ Sequence 836 AA;

Query Match 99.8%; Score 4387; DB 5; Length 836;  
 Best Local Similarity 99.9%; Pred. No. 0;  
 Matches 835; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy	1	MAGLNCGVSIALLGVLLLGAARLPRGAEAFEIALPRESNITVLIKLGTPPTLLAKPCYIVI	60
Db	1	MAGLNCGVSIALLGVLLLGAARLPRGAEAFEIALPRESNITVLIKLGTPPTLLAKPCYIVI	60
Qy	61	SKRHITMSIKSGERIVFTFSCQSPENHFVIEIQKNIDCMMSGPCPFGEVQLQPSTSLPT	120
Db	61	SKRHITMSIKSGERIVFTFSCQSPENHFVIEIQKNIDCMMSGPCPFGEVQLQPSTSLPT	120
Qy	121	LNRTFIWDVKAHKSIGLELQFSIPRLRQIGPGESCPDGVTHSISGRIDATVVRIGTFCSN	180
Db	121	LNRTFIWDVKAHKSIGLELQFSIPRLRQIGPGESCPDGVTHSISGRIDATVVRIGTFCSN	180
Qy	181	GTVSRIKMQEGVKMALHLPWFHPRNVSGFSIANRSSIKRLCIIESVFEGEGSATLMSANY	240
Db	181	GTVSRIKMQEGVKMALHLPWFHPRNVSGFSIANRSSIKRLCIIESVFEGEGSATLMSANY	240
Qy	241	PEGFPEDELMTWQFVVPAPHLRASVSFLNFNLSNCERKEERVEYYIPGSTTNPEVFKLEDK	300
Db	241	PEGFPEDELMTWQFVVPAPHLRASVSFLNFNLSNCERKEERVEYYIPGSTTNPEVFKLEDK	300
Qy	301	QPGNMAGNFNLSLQGCDDAQSPGILRLQFQVLVQHPQNESNKIYVVDLSNERAMSLTIE	360
Db	301	QPGNMAGNFNLSLQGCDDAQSPGILRLQFQVLVQHPQNESNKIYVVDLSNERAMSLTIE	360
Qy	361	PRPVKQSRKFVPGCFVCLESRTCSSNLTLSGSKHKISFLCDDLTRLWMNVEKTISCTDH	420
Db	361	PRPVKQSRKFVPGCFVCLESRTCSSNLTLSGSKHKISFLCDDLTRLWMNVEKTISCTDH	420
Qy	421	RYCQRKSYSLSQVPSDILHLPVELHDFSWKLLVPKDRLSLVLVPAQKLQQTKEKPCNTSF	480
Db	421	RYCQRKSYSLSQVPSDILHLPVELHDFSWKLLVPKDRLSLVLVPAQKLQQTKEKPCNTSF	480
Qy	481	SYLVASAIPSQDLYFGSFCPGGSIKQIQVKQNISVTLRTFAPSFQQEASRQGLTVSFIPY	540
Db	481	SYLVASAIPSQDLYFGSFCPGGSIKQIQVKQNISVTLRTFAPSFQQEASRQGLTVSFIPY	540
Qy	541	FKEEGVFTVTPDTKSKVYLRTPNWDRGLPSLTSVSWNISVPRDQVACLTFKERSGVVCQ	600
Db	541	FKEEGVFTVTPDTKSKVYLRTPNWDRGLPSLTSVSWNISVPRDQVACLTFKERSGVVCQ	600
Qy	601	TGRAFMIIQEQRTAAEIFSLDEDVLPKPSFHHSFVWNISNCSPTSGKQLDLLFSVTLT	660
Db	601	TGRAFMIIQEQRTAAEIFSLDEDVLPKPSFHHSFVWNISNCSPTSGKQLDLLFSVTLT	660

Qy	661	PRTVDLTVILIAAVGGGVLLLSALGLIICCVKKKKKKTKNGPAVGIYNDNINTEMPRQPK	720
Db	661	PRTVDLTVILIAAVGGGVLLLSALGLIICCVKKKKKKTKNGPAVGIYNGNINTEMPRQPK	720
Qy	721	KFQKGRKDNDSHVYAVIEDTMVYGHLLQDSSGSFLQPEVD TYRPFQGTMGVCPPSPPTIC	780
Db	721	KFQKGRKDNDSHVYAVIEDTMVYGHLLQDSSGSFLQPEVD TYRPFQGTMGVCPPSPPTIC	780
Qy	781	SRAPTAKLATEEPPPRSPPESESEPYTF SHPNNGDVSSKDTDIPLLNTQEPMEPAE	836
Db	781	SRAPTAKLATEEPPPRSPPESESEPYTF SHPNNGDVSSKDTDIPLLNTQEPMEPAE	836

<!--EndFragment-->